Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF, which has gained 1.2% with a trading volume of 351 million yuan and a total fund size of 2.079 billion yuan as of November 10 [1] - Key performing stocks within the ETF include InnoCare Pharma-B, Bionet, and Ascletis Pharma, with respective gains of 5.4%, 4.43%, and 4.37% [1] - Conversely, stocks such as Kangzhe Pharmaceutical, MIRXES-B, and Innovent Biologics showed weaker performance, with declines of 1.28%, 0.94%, and 0.65% respectively [1] Group 2 - The innovative drug sector is identified as the largest investment opportunity in the pharmaceutical sector for 2025, with a focus on dual/multi-target drugs, chronic disease medications addressing unmet clinical needs, and ADCs [2] - There is a noted improvement in domestic and international innovative drug financing data, with an upward trend in CXO industry orders, indicating a potential recovery in valuations and performance [2] - The medical device sector is experiencing accelerated approvals for innovative products, such as the approval of the chest and abdominal aortic stent system by Xianjian Technology, which is expected to enhance long-term profit margins [2] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF and its linked funds passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with the top ten weighted stocks including BeiGene, China Biologic Products, and Innovent Biologics [3]

Core Insights - The article discusses the recent financial performance of a leading company in the technology sector, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $10 billion, representing a 20% increase year-over-year [1] - Net income reached $2 billion, which is a 25% increase from the last fiscal year [1] - Earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating a 25% growth [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the last quarter [1] - The technology sector overall is experiencing robust growth, with a projected annual growth rate of 15% over the next five years [1] Strategic Initiatives - The company has launched several new products that contributed to the revenue growth, with one product alone accounting for $1 billion in sales [1] - Investments in research and development have increased by 30%, reflecting the company's commitment to innovation [1] Future Outlook - Analysts predict continued growth for the company, with expected revenue of $12 billion next year, marking a 20% increase [1] - The company plans to expand into new international markets, which could further enhance its growth trajectory [1]

公司名稱: 亞盛醫藥集團 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06855 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | | --- | | 2025年10月31日 | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 本月底法定/註冊股本 ...

Core Insights - The company has announced multiple clinical and preclinical advancements for three products (Nailike®, Lishengtuo®, APG-5918) selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, with one receiving an oral presentation [1] - The company's original first-in-class drug, Orebatinib (Nailike®), has been selected for the ASH meeting for the eighth consecutive year, highlighting its ongoing clinical progress [1] - The original first-in-class drug, Lishatoclax (Lishengtuo®; R&D code: APG-2575), has two clinical advancements selected for the ASH meeting, marking its fourth consecutive year of selection [1] Product Developments - Nailike® is the first third-generation BCR-ABL inhibitor approved in China, with commercialization jointly managed by the company and Innovent Biologics. The company will present the latest data from the global Phase III POLARIS-1 study on Nailike® combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients at the ASH meeting [2] - The company will also update data from a randomized controlled Phase II study on Nailike® for patients with tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia in chronic phase (CML-CP) and data for second-line treatment of non-T315I mutation CML-CP patients [2] - Lishatoclax is a novel oral Bcl-2 selective inhibitor developed by the company, approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment including a Bruton tyrosine kinase (BTK) inhibitor. The company will present the latest advancements from a registered Phase II clinical study on Lishatoclax for relapsed/refractory (R/R) CLL/SLL patients [2] Event Information - The 67th ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases. The event will take place from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]

Core Insights - Ascentage Pharma (亚盛医药-B) announced that three of its products (Neratinib, Lisatinib, APG-5918) have multiple clinical and preclinical advancements selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, with one receiving an oral presentation [1][2] Group 1: Product Developments - Neratinib (耐立克) is the first third-generation BCR-ABL inhibitor approved in China, with commercialization jointly managed by Ascentage Pharma and Innovent Biologics. The company will present the latest data from the global Phase III POLARIS-1 study on Neratinib combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients at the ASH meeting [2] - The company will also update data from a randomized controlled Phase II study on Neratinib for patients with tyrosine kinase inhibitor-resistant chronic myeloid leukemia in chronic phase (CML-CP) during the conference [2] - Lisatinib (利生妥), a novel oral Bcl-2 selective inhibitor developed by Ascentage Pharma, has broad therapeutic potential in various hematological malignancies and solid tumors. It has been approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment including a Bruton tyrosine kinase (BTK) inhibitor. The latest progress of its Phase II clinical study for monotherapy in relapsed/refractory CLL/SLL patients will be reported orally at the ASH meeting [2] Group 2: ASH Annual Meeting - The ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases. The 67th ASH Annual Meeting will be held from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]

Core Insights - The company, Ascentage Pharma-B (06855), announced multiple clinical and preclinical advancements for three products (Orebactin®, Lisatoclax®, APG-5918) selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, including one oral presentation [1] - Orebactin® has been selected for ASH for eight consecutive years, showcasing its ongoing clinical progress [1] - Lisatoclax® has two clinical advancements selected for ASH, marking its fourth consecutive year of inclusion [1] Group 1: Product Developments - Orebactin® is the first approved third-generation BCR-ABL inhibitor in China, with commercialization jointly managed by Ascentage Pharma and Innovent Biologics [2] - At the ASH meeting, the company will present the latest data from the global Phase III POLARIS-1 study on Orebactin® combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients [2] - The company will also update data from a randomized controlled Phase II study on Orebactin® for TKI-resistant chronic myeloid leukemia in chronic phase (CML-CP) patients, including four-year follow-up data [2] Group 2: Lisatoclax® Insights - Lisatoclax® is a novel oral Bcl-2 selective inhibitor developed by Ascentage Pharma, showing potential in treating various hematological malignancies and solid tumors [2] - The product has been approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment, including a Bruton tyrosine kinase (BTK) inhibitor [2] - The company will present the latest advancements from a registered Phase II clinical study of Lisatoclax® as a monotherapy for relapsed/refractory CLL/SLL patients, along with data on its combination with azacitidine for newly diagnosed or previously venetoclax-treated myeloid tumor patients [2] Group 3: ASH Annual Meeting - The ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases [3] - The 67th ASH Annual Meeting will take place from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的全部內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ASCENTAGE PHARMA GROUP INTERNATIONAL 亞盛醫藥集團 （於開曼群島註冊成立的有限公司） （股份代號：6855） 自願公告 亞盛醫藥耐立克®、利生妥®、APG-5918的多項臨床進展將 在2025年美國血液學會年會(ASH)展示，其中一項獲口頭報告 亞盛醫藥集團（「本公司」或「亞盛醫藥」）欣然宣佈，本公司3個品種（耐立克®、利 生妥®、APG-5918）有多項臨床和臨床前進展入選第67屆美國血液學會(American Society of Hematology, ASH)年會展示及報告，其中一項獲口頭報告。其中，本 公司原創1類新藥奧雷巴替尼（商品名：耐立克®）有多項臨床進展獲選第67屆ASH 年會，這是該品種的臨床進展連續第8年入選ASH年會。此外，本公司原創1類新 藥利沙托克拉（商品名：利生妥®；研發代碼：APG-2575）共有2項臨床進展獲選 第67屆ASH年會， ...

Group 1 - A-shares and Hong Kong stocks in the innovative pharmaceutical sector have rebounded, with significant gains in related stocks and ETFs [1][3][5] - The largest medical ETF in A-shares (512170) saw a trading volume of 589 million yuan, recovering 1.34% on the day [1] - The innovative drug sector is experiencing a collective rise, with notable stocks like Huahai Pharmaceutical increasing by 7.59% [3] Group 2 - The Hong Kong innovative drug ETF (520880) rose by 2.12%, with 35 out of 37 constituent stocks gaining, led by Green Leaf Pharmaceutical with an 8.31% increase [5][7] - Recent funding trends indicate a significant inflow into the innovative drug sector, with over 1.29 billion yuan added in the last three days [7] - Upcoming catalysts include the European Society for Medical Oncology (ESMO) annual meeting, which may showcase significant research results from Chinese innovative drugs [7] Group 3 - Investment strategies suggest focusing on innovative drugs, with specific ETFs like the Hong Kong innovative drug ETF (520880) and the A-share drug ETF (562050) highlighted for their potential [8] - The medical ETF (512170) is noted for its inclusion of CXO companies, which account for 26.77% of its weight [8] - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9]